Carbocisteine

證據等級: L5

預測適應症: 10 個

Carbocisteine: From Mucolytic Agent to Bronchitis

One-Sentence Summary

Carbocisteine is a well-established mucoregulatory drug used for respiratory conditions in many countries, though it is not currently registered in Singapore. The TxGNN model predicts it may be effective for Bronchitis — the strongest evidence-backed prediction among all candidates — supported by 1 clinical trial and 20 publications, including multiple Cochrane systematic reviews and double-blind RCTs. Among the 10 TxGNN-predicted indications, bronchitis carries L1 evidence and is the only actionable candidate; the remaining predictions are rated L4–L5 or flagged as knowledge graph artefacts.

Quick Overview

Item	Content
Original Indication	Not currently registered in Singapore (established use for viscous mucus-associated respiratory disorders in UK, EU, and Japan)
Predicted New Indication	Bronchitis
TxGNN Prediction Score	98.77%
Evidence Level	L1
Singapore Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Carbocisteine (S-carboxymethyl-L-cysteine) is a mucoregulatory agent that works through three well-characterised pathways. First, it restructures mucus glycoproteins by downregulating MUC5AC — the gel-forming mucin responsible for the abnormally thick secretions seen in bronchitis — while relatively preserving MUC5B, which has more favourable viscoelastic properties for expectoration. Second, it acts as a direct reactive oxygen species (ROS) scavenger, reducing oxidative stress in inflamed airways. Third, it enhances mucociliary clearance by restoring normal ciliary function, which is impaired in chronic airway disease. Although detailed MOA data are not yet available from DrugBank in this Evidence Pack, the mechanisms above are well-documented in the peer-reviewed literature (e.g., PMID 8500784, PMID 19144049, PMID 15205558).

Bronchitis — both acute and chronic — is characterised precisely by mucus hypersecretion, impaired mucociliary transport, and airway inflammation: the three pathological targets that carbocisteine directly addresses. In chronic bronchitis and COPD, excess MUC5AC production and reduced ciliary beat frequency are central to the cycle of exacerbation and hospitalisation. Carbocisteine's ability to normalise mucus rheology, reduce bacterial airway load (PMID 20807377), and suppress NF-κB-mediated inflammation creates a mechanistic rationale that is among the most coherent of any mucolytic agent.

Carbocisteine has been licensed for respiratory indications in the United Kingdom, France, Japan, and other jurisdictions for decades. Multiple Cochrane systematic reviews and independent RCTs confirm reductions in exacerbation frequency and symptomatic improvement in patients with chronic bronchitis and COPD. The Singapore market, where the drug is currently absent, represents a regulatory white space for an indication that is not novel globally — making the repurposing pathway more a market-entry exercise than a first-in-class development programme.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02858193	Phase 1	Completed	30	2-way crossover bioequivalence study comparing carbocisteine-L-lysine salt 1.35 g powder for oral solution vs 90 mg/mL syrup in healthy volunteers under fasting conditions; confirmed bioequivalent Cmax and AUC0-t — supports formulation flexibility for market entry

Literature Evidence

PMID	Year	Type	Journal	Key Findings
3907681	1985	RCT (Double-blind, Placebo-controlled)	Br J Clin Pract	Long-term oral carbocisteine vs placebo in chronic bronchitis; direct efficacy endpoint
789027	1976	RCT (Double-blind, 3-month)	Chest	n=82 chronic bronchitis patients; S-carboxymethylcysteine reduced sputum viscosity and improved expectoration capacity vs placebo
2099568	1990	Controlled Study (Double-blind)	Respiration	n=24 chronic bronchitis outpatients; single high-dose carbocisteine-lysine produced significant viscosity reductions (−67%) persisting 8 days post-treatment
31107966	2019	Cochrane SR + Meta-analysis	Cochrane Database Syst Rev	Largest pooled analysis (26 studies) of mucolytics vs placebo in chronic bronchitis/COPD; supports reduction in exacerbation frequency with mucolytics including carbocisteine
39413571	2024	Systematic Review	Respiratory Investigation	Most recent meta-analysis of mucolytics in stable COPD; evaluates efficacy and safety endpoints including exacerbation rate
23728642	2013	Cochrane Review	Cochrane Database Syst Rev	Acetylcysteine and carbocysteine for acute RTIs in paediatric patients; safety and efficacy review in children without chronic bronchopulmonary disease
19160217	2009	Cochrane Review	Cochrane Database Syst Rev	Earlier Cochrane edition on carbocisteine for acute RTIs in children; flags limited evidence for acute paediatric use
20956182	2010	Review	Eur Respir Rev	Mucoactive therapy in COPD; reviews carbocisteine evidence including effects on FEV₁ decline, hospitalisations, and mortality risk
30670922	2019	Review	Clin Med Insights ENT	Confirms carbocysteine's well-established status with regulatory approval in multiple countries; notes OTC/prescription availability
18832259	2008	Review	Drug Ther Bull	Compares mucolytics for COPD exacerbations; notes carbocisteine and mecysteine are licensed for long-term use in viscous-mucus respiratory disorders, distinct from erdosteine's short-course licence

Singapore Market Information

Carbocisteine is not currently registered in Singapore. No product authorisations were found in the Singapore HSA database.

For reference, the drug holds marketing authorisation in the following jurisdictions under the trade name Mucodyne (UK), Rhinathiol (France), and Mucosolvan/Mucodyne (Japan), covering indications including chronic bronchitis, COPD, and upper respiratory tract disorders with viscous secretions.

Safety Considerations

Formal safety data (package insert warnings, contraindications, and drug-drug interactions) are not available for the Singapore context in this Evidence Pack.

Please refer to the package insert from an approved jurisdiction (e.g., UK SmPC or EU Summary of Product Characteristics) for complete safety information.

Safety signal from literature: A case report (PMID 23291681, 2013) documents confirmed carbocisteine-induced pneumonia in a 32-year-old patient with CATCH22 syndrome (DiGeorge/22q11.2 deletion), an immunocompromised condition. Drug-lymphocyte stimulation test was positive. This suggests that patients with primary immunodeficiency or chromosomal deletion syndromes may require additional risk assessment before initiating therapy.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Carbocisteine has L1 evidence for bronchitis and chronic obstructive pulmonary disease, supported by multiple Cochrane systematic reviews and double-blind placebo-controlled RCTs spanning four decades. The drug is already licensed in major markets (UK, EU, Japan), meaning safety and efficacy data are accessible through established regulatory filings — significantly lowering the development burden for a Singapore market application.

To proceed, the following is needed:

Regulatory pathway confirmation: Engage Singapore HSA to determine whether an abridged NDA (referencing UK/EU approval) or a full submission is required, given the absence of any current Singapore registration
Safety dossier extraction: Obtain the UK SmPC or EU SmPC to formally document contraindications, special population warnings (paediatric, renal impairment, pregnancy), and known drug interactions
Drug-drug interaction profile: Re-query DrugBank API and the WHO DDI database; current DDI search returned zero results, which likely reflects a data gap rather than absence of interactions
Paediatric use assessment: Cochrane reviews (PMID 23728642, 19160217) indicate limited evidence for acute use in children without chronic lung disease; a paediatric risk-benefit statement will be needed for any label targeting this population
Formulation decision: Determine whether to enter the Singapore market as oral syrup, capsule, or granule for oral solution, informed by the bioequivalence data from NCT02858193
Immunocompromised population warning: Incorporate CATCH22 and other primary immunodeficiency conditions as a precautionary contraindication or monitoring requirement, based on PMID 23291681
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.